Dr. Hall on Multigene Target Panels for Genetic Weaknesses

Michael J. Hall, MD
Published: Thursday, Jul 02, 2015



Michael J. Hall, MD, MS, director, Gastrointestinal Risk Assessment, assistant professor, Fox Chase Cancer Center, discusses multigene target panels that examine tumors for genetic weaknesses.

Multigene panels have been developed for practitioners to evaluate tumors for genetic and genomic weaknesses, Hall explains. However, the fact that detected mutations within tumors are reflective of potential germline variations is understudied. This should be a significant area of research, Hall adds, because patients may be at risk for other cancers or may be unaware of risks associated with their family history.

In a collaboration between Fox Chase Cancer Center and Foundation Medicine, a multigene target panel tested approximately 15,000 tumors. Researchers examined a subset of the tested genes that were known for hereditary cancer risk to determine how many of them were pathogenic.
 
SELECTED
LANGUAGE


Michael J. Hall, MD, MS, director, Gastrointestinal Risk Assessment, assistant professor, Fox Chase Cancer Center, discusses multigene target panels that examine tumors for genetic weaknesses.

Multigene panels have been developed for practitioners to evaluate tumors for genetic and genomic weaknesses, Hall explains. However, the fact that detected mutations within tumors are reflective of potential germline variations is understudied. This should be a significant area of research, Hall adds, because patients may be at risk for other cancers or may be unaware of risks associated with their family history.

In a collaboration between Fox Chase Cancer Center and Foundation Medicine, a multigene target panel tested approximately 15,000 tumors. Researchers examined a subset of the tested genes that were known for hereditary cancer risk to determine how many of them were pathogenic.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Addressing Post-Transplant Obstacles: Current and Emerging Strategies to Evolve the Standard of Care for Patients With Graft-Versus-Host DiseaseMar 28, 20192.0
2017 Year in Review™: Clinical Impact of Immunotherapies in the Treatment of CancerMar 30, 20191.75
Publication Bottom Border
Border Publication
x